18299-1-AP

antibody from Proteintech Group

Targeting: ERBB2 CD340, HER-2, HER2, NEU, NGL

Western blot (Supportive data in Antibodypedia)

ELISA (Data presented on provider website)

Immunocytochemistry (Data presented on provider website)

Immunoprecipitation (Data presented on provider website)

Immunohistochemistry (Supportive data in Antibodypedia)

Flow cytometry (Supportive data in Antibodypedia)

Antibody Data

Product number

18299-1-AP

Provider

Proteintech Group

Proper citation

Proteintech Cat#18299-1-AP, RRID:AB_2099264

Product name

HER2/ErbB2 antibody

Antibody type

Polyclonal

Description

HER2/ErbB2 antibody (Cat. #18299-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: FC, IF, IHC, IP, WB,ELISA.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

Upregulation of estrogen receptor alpha (ERα) expression in transgenic mice expressing human CYP4Z1.

Khayeka-Wandabwa C, Zhao J, Pathak JL, Wu H, Bureik M
Breast cancer research and treatment 2022 Jan;191(2):319-326

---

Rolling Circle Amplification-Assisted Flow Cytometry Approach for Simultaneous Profiling of Exosomal Surface Proteins.

Gao X, Teng X, Dai Y, Li J
ACS sensors 2021 Oct 22;6(10):3611-3620

---

PET-CT and RNA sequencing reveal novel targets for acupuncture-induced lowering of blood pressure in spontaneously hypertensive rats.

Li J, Peng C, Lai D, Fang Y, Luo D, Zhou Z, Li C, Lai X
Scientific reports 2021 May 26;11(1):10973

---

CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.

Li H, Wang J, Yi Z, Li C, Wang H, Zhang J, Wang T, Nan P, Lin F, Xu D, Qian H, Ma F
European journal of cancer (Oxford, England : 1990) 2021 Mar;145:92-108

---

MicroRNA-133a-3p suppresses malignant behavior of non-small cell lung cancer cells by negatively regulating ERBB2.

Xu Y, Zhang L, Xia L, Zhu X
Oncology letters 2021 Jun;21(6):457

---

Formin-like protein 2 promotes cell proliferation by a p27-related mechanism in human breast cancer cells.

Jiao X, Wang B, Feng C, Song S, Tian B, Zhou C, Gao X, Sun W, Liu P
BMC cancer 2021 Jun 30;21(1):760

---

NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells.

Liu WJ, Huang YX, Wang W, Zhang Y, Liu BJ, Qiu JG, Jiang BH, Liu LZ
Cells 2021 Jun 30;10(7)

---

HER2 targeting near-infrared photoimmunotherapy for a CDDP-resistant small-cell lung cancer.

Takahashi K, Taki S, Yasui H, Nishinaga Y, Isobe Y, Matsui T, Shimizu M, Koike C, Sato K
Cancer medicine 2021 Dec;10(24):8808-8819

---

Modulating cancer stemness provides luminal a breast cancer cells with HER2 positive-like features.

Mei Y, Cai D, Dai X
Journal of Cancer 2020;11(5):1162-1169

---

Target molecular treatment markers in Intrahepatic Cholangiocarcinoma based on Chinese population.

Pu X, Zhu L, Li F, Zheng J, Wu H, Fu Y, Chen J, Qi L
Pathology, research and practice 2020 Sep;216(9):153116

---

Aptamer Enables Consistent Maytansine Delivery through Maintaining Receptor Homeostasis for HER2 Targeted Cancer Therapy.

Tan Y, Peng Y, Ai L, Li Y, Qu YX, Wang D, Su Y, Deng T, Fu T, Zhao Z, Wang XQ, Tan W
Bioconjugate chemistry 2020 Jul 15;31(7):1766-1774

---

An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.

Yang ZY, Yang L, Xu CW, Wang XJ, Lei L
Biology open 2020 Jan 24;9(1)

---

CMIP promotes Herceptin resistance of HER2 positive gastric cancer cells.

Xiang R, Han X, Ding K, Wu Z
Pathology, research and practice 2020 Feb;216(2):152776

---

BML-111 inhibits EMT, migration and metastasis of TAMs-stimulated triple-negative breast cancer cells via ILK pathway.

Lin L, Luo X, Wang L, Xu F, He Y, Wang Q, Yuan C, Xu J, Yan L, Hao H
International immunopharmacology 2020 Aug;85:106625

---

SEMA3C Promotes Cervical Cancer Growth and Is Associated With Poor Prognosis.

Liu R, Shuai Y, Luo J, Zhang Z
Frontiers in oncology 2019;9:1035

---

Efficient Acquisition of Fully Human Antibody Genes against Self-Proteins by Sorting Single B Cells Stimulated with Vaccines Based on Nitrated T Helper Cell Epitopes.

Jiang L, Jiang T, Luo J, Kang Y, Tong Y, Song X, Gao X, Yao W, Tian H
Journal of immunology research 2019;2019:7914326

---

FOXA1 is Prognostic of Triple Negative Breast Cancers by Transcriptionally Suppressing SOD2 and IL6.

Dai X, Cheng H, Chen X, Li T, Zhang J, Jin G, Cai D, Huang Z
International journal of biological sciences 2019;15(5):1030-1041

---

ANLN and KDR Are Jointly Prognostic of Breast Cancer Survival and Can Be Modulated for Triple Negative Breast Cancer Control.

Dai X, Mei Y, Chen X, Cai D
Frontiers in genetics 2019;10:790

---

Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers.

Wang D, Hu X, Liu C, Jia Y, Bai Y, Cai C, Wang J, Bai L, Yang R, Lin C, Liu YR, Li S, Qiao F, Yao L, Chen L, Ge G, Jiang H, Li D, Li L, Chen J, Shao ZM, Zeng YA
Cell research 2019 Oct;29(10):832-845

---

Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1.

Namba M, Hattori N, Hamada H, Yamaguchi K, Okamoto Y, Nakashima T, Masuda T, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Kohno N
Cancer letters 2019 Feb 1;442:31-39

---

The antimetastatic effect and underlying mechanisms of thioredoxin reductase inhibitor ethaselen.

Zheng X, Chen Y, Bai M, Liu Y, Xu B, Sun R, Zeng H
Free radical biology & medicine 2019 Feb 1;131:7-17

---

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.

Liu Y, Xu J, Choi HH, Han C, Fang Y, Li Y, Van der Jeught K, Xu H, Zhang L, Frieden M, Wang L, Eyvani H, Sun Y, Zhao G, Zhang Y, Liu S, Wan J, Huang C, Ji G, Lu X, He X, Zhang X
Nature communications 2018 Nov 9;9(1):4718

---

Protein C receptor stimulates multiple signaling pathways in breast cancer cells.

Wang D, Liu C, Wang J, Jia Y, Hu X, Jiang H, Shao ZM, Zeng YA
The Journal of biological chemistry 2018 Jan 26;293(4):1413-1424

---

Crucial microRNAs and genes in metformin's anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis.

Li Y, Li L, Zhang G, Wang Y, Chen H, Kong R, Pan S, Sun B
Investigational new drugs 2018 Feb;36(1):20-27

---

Simvastatin inhibits tumor angiogenesis in HER2-overexpressing human colorectal cancer.

Li G, Zheng J, Xu B, Ling J, Qiu W, Wang Y
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2017 Jan;85:418-424

---

Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.

Zhang WJ, Li Y, Wei MN, Chen Y, Qiu JG, Jiang QW, Yang Y, Zheng DW, Qin WM, Huang JR, Wang K, Zhang WJ, Wang YJ, Yang DH, Chen ZS, Shi Z
Cancer letters 2017 Feb 1;386:100-109

---

Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.

Tan S, Ding K, Chong QY, Zhao J, Liu Y, Shao Y, Zhang Y, Yu Q, Xiong Z, Zhang W, Zhang M, Li G, Li X, Kong X, Ahmad A, Wu Z, Wu Q, Zhao X, Lobie PE, Zhu T
The Journal of biological chemistry 2017 Aug 18;292(33):13551-13564

---

Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.

Zhang Z, Li HM, Zhou C, Li Q, Ma L, Zhang Z, Sun Y, Wang L, Zhang X, Zhu B, Hong YS, Wu CZ, Liu H
Journal of experimental & clinical cancer research : CR 2016 Sep 22;35(1):149

---

Novel method to rescue a lethal phenotype through integration of target gene onto the X-chromosome.

Sakata K, Araki K, Nakano H, Nishina T, Komazawa-Sakon S, Murai S, Lee GE, Hashimoto D, Suzuki C, Uchiyama Y, Notohara K, Gukovskaya AS, Gukovsky I, Yamamura KI, Baba H, Ohmuraya M
Scientific reports 2016 Nov 15;6:37200

---

HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth.

Lu Y, Wang Y, Zhang M, Liu L, Li F, Zhang J, Ye M, Zhao H, Zhao J, Yan B, Yang A, Zhang R, Li X, Ren X
Oncotarget 2016 Apr 26;7(17):23594-607

---

Cellular stress induces cap-independent alpha-enolase/MBP-1 translation.

Maranto C, Perconti G, Contino F, Rubino P, Feo S, Giallongo A
FEBS letters 2015 Jul 22;589(16):2110-6

---

Negative transcriptional control of ERBB2 gene by MBP-1 and HDAC1: diagnostic implications in breast cancer.

Contino F, Mazzarella C, Ferro A, Lo Presti M, Roz E, Lupo C, Perconti G, Giallongo A, Feo S
BMC cancer 2013 Feb 19;13:81

---

Effect of acute acid-base disturbances on ErbB1/2 tyrosine phosphorylation in rabbit renal proximal tubules.

Skelton LA, Boron WF
American journal of physiology. Renal physiology 2013 Dec 15;305(12):F1747-64

Western blot

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

HeLa cells were subjected to SDS PAGE followed by western blot with 18299-1-AP(ERBB2,p185-Specific antibody) at dilution of 1:2000

Sample type

cell line

Immunohistochemistry

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

Immunohistochemical of paraffin-embedded human breast cancer using 18299-1-AP(ERBB2,p185-Specific antibody) at dilution of 1:50 (under 10x lens)

Sample type

tissue

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

Immunohistochemical of paraffin-embedded human breast cancer using 18299-1-AP(ERBB2,p185-Specific antibody) at dilution of 1:50 (under 40x lens)

Sample type

tissue

Flow cytometry

Supportive validation

Submitted by

Proteintech Group (provider)

Main image

Experimental details

The HER2/ErbB2 antibody from Proteintech is a rabbit polyclonal antibody to a peptide of human HER2/ErbB2. This antibody recognizes human,mouse,rat antigen. The HER2/ErbB2 antibody has been validated for the following applications: ELISA, WB, IHC, FC analysis.

Appendix

18299-1-AP.pdf

Show more